title: Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update.
abstract: Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (≥20-30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival <1 year) and the poor response to chemotherapy in these pts, this sub-group analysis evaluated the effects of AZA versus conventional care regimens (CCR) on OS and on response rates in pts with WHO AML.
authors.affiliation: Hôpital Avicenne, Université Paris 13, Bobigny, France. pierre.fenaux@avc.aphp.fr
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
authors.forename: G J
authors.initials: GJ
authors.lastname: Mufti
authors.forename: E
authors.initials: E
authors.lastname: Hellström-Lindberg
authors.forename: V
authors.initials: V
authors.lastname: Santini
authors.forename: N
authors.initials: N
authors.lastname: Gattermann
authors.forename: G
authors.initials: G
authors.lastname: Sanz
authors.forename: A F
authors.initials: AF
authors.lastname: List
authors.forename: S D
authors.initials: SD
authors.lastname: Gore
authors.forename: J F
authors.initials: JF
authors.lastname: Seymour
authors.forename: J
authors.initials: J
authors.lastname: Backstrom
authors.forename: L
authors.initials: L
authors.lastname: Zimmerman
authors.forename: D
authors.initials: D
authors.lastname: McKenzie
authors.forename: C L
authors.initials: CL
authors.lastname: Beach
authors.forename: L B
authors.initials: LB
authors.lastname: Silverman